Ocugen (OCGN)
(Delayed Data from NSDQ)
$1.70 USD
-0.11 (-6.08%)
Updated May 14, 2024 04:00 PM ET
After-Market: $1.70 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
OCGN 1.70 -0.11(-6.08%)
Will OCGN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for OCGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OCGN
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
OCGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocugen Q2 Preview: Rebound Quarter Inbound?
Implied Volatility Surging for Ocugen (OCGN) Stock Options
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
Other News for OCGN
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript
OCGN Stock Earnings: Ocugen Beats EPS for Q1 2024
Ocugen Provides Business Update with First Quarter 2024 Financial Results
Ocugen to begin dosing in Phase 3 liMeliGhT trial in Q2